“…In this Review, bioadjuvants just refer to the ligands for pattern recognition receptors (PRR), including toll‐like receptors (TLRs), NOD‐like receptors (NLRs), RIG‐I‐like receptors (RLRs), and C‐type lectin receptors (CLRs), which predominantly target the antigen‐presenting cells, inducing the innate immunity, and consequently influencing the adaptive immune responses. Among numerous available bioadjuvants, TLR agonists have been intensely investigated, such as CpG, poly(I:C), monophosphoryl lipid A (MPLA), lipopolysaccharide (LPS), and resiquimod (R848), which show higher efficiency in the form of delivery nanovectors than free soluble form . Interestingly, a polymeric nanocomplex encapsulating low dose of paclitaxel, a kind of anticancer drug, displayed an adjuvant function to hinder immunologic escape and activate cancer immunotherapy …”